RCS - Spexis AG - Strategy Update and 2021 Financial Results

Spexis AGAnnouncement

09/03/2022 08:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220309:nRSI1632Ea&default-theme=true

RNS Number : 1632E  Spexis AG  09 March 2022

 Spexis AG / Key word(s): Annual Results

Spexis to present strategy update and full-year 2021 financial results on
 March 24, 2022

09-March-2022

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.

 Ad hoc announcement pursuant to Art. 53 LR

 Allschwil, Switzerland, March 9, 2022

Spexis to present strategy update and full-year 2021 financial results on
 March 24, 2022

 Spexis AG (SIX: SPEX) announced today that it will publish its full-year
 financial results for 2021 on March 24 at 7.30am CET.

 Jeffrey D. Wager, M.D. (CEO & Chairman) and Hernan Levett (CFO) will host
 an earnings call at 2.30pm CET, together with Juergen Froehlich, M.D. (CMDO)
 and Stephan Wehselau (COO). To access the earnings call, please use the
 following details:

 France: +33 (0)1 70 730 3 39

Germany: +49 (0)69 22222 5197

Italy: +39 02 3602 6066

Switzerland +41 (0)44 580 7279

United Kingdom +44 (0)330 165 4012

United States +1 646-828-8073

 Event Title: Spexis AG - Strategy Update and 2021 Financial Results

 Confirmation code: 4015509

The presentation will also be available via webcast:
 https://www.webcast-eqs.com/spexis20220324
 (https://che01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.webcast-eqs.com%2Fspexis20220324&data=04%7C01%7CHernan.Levett%40spexisbio.com%7Cc890ec0d7e13432ba6c508d9fdc5d491%7Cc13de0c0b4d3464c93a923fcbc19b97f%7C0%7C0%7C637819848427736353%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=XtkY0lfN%2BgGGKzb21D5awr4YULoKN0MKbe9Sq7fnSW4%3D&reserved=0)

 Link for participants of the conference call (only slides, no audio, no
 delay): https://www.webcast-eqs.com/spexis20220324/no-audio
 (https://che01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.webcast-eqs.com%2Fspexis20220324%2Fno-audio&data=04%7C01%7CHernan.Levett%40spexisbio.com%7Cc890ec0d7e13432ba6c508d9fdc5d491%7Cc13de0c0b4d3464c93a923fcbc19b97f%7C0%7C0%7C637819848427736353%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=nX%2Bss5DeS7tSoG5ATzbCwPzgsI%2BS2XgvkctsPtw7Ux0%3D&reserved=0)

 After the call, the presentation will be available via the above link.

 For further information please contact:

For Investors:                               For Media:

Hernan Levett
 Dr. Stephan Feldhaus

Chief Financial Officer
 Feldhaus & Partner

Spexis AG.
 +41 79 865 92 56

+41 61 567 16 00                            feldhaus@feldhaus-partner.ch (mailto:feldhaus@feldhaus-partner.ch)
 IR@spexisbio.com (mailto:IR@spexisbio.com)

 

 About Spexis

Spexis is a clinical-stage biopharmaceutical company based in Allschwil,
 Switzerland, focused on rare diseases and oncology. The current pipeline of
 the company is a combination of two legacy companies, Polyphor AG and
 EnBiotix, Inc. (Boston, MA, USA) which merged in December 2021. The combined
 company has been renamed to Spexis AG and is trading on the SIX Swiss Exchange
 under the symbol SIX:SPEX. For further information please visit:
 www.spexisbio.com (http://www.spexisbio.com/) .

 Disclaimer

This press release contains forward-looking statements which are based on
 current assumptions and forecasts of Spexis management. Known and unknown
 risks, uncertainties, and other factors could lead to material differences
 between the forward-looking statements made here and the actual development,
 in particular Spexis' results, financial situation, and performance. Readers
 are cautioned not to put undue reliance on forward-looking statements, which
 speak only of the date of this communication. Spexis disclaims any intention
 or obligation to update and revise any forward-looking statements, whether as
 a result of new information, future events or otherwise.

 Additional features:

File: Spexis to announce FY2021 Financial Results
 (https://eqs-cockpit.com/c/fncls.ssp?u=739492cdc357bbb5cd23167f50d838d6)

 End of ad hoc announcement

 

About Spexis

Spexis is a clinical-stage biopharmaceutical company based in Allschwil,
Switzerland, focused on rare diseases and oncology. The current pipeline of
the company is a combination of two legacy companies, Polyphor AG and
EnBiotix, Inc. (Boston, MA, USA) which merged in December 2021. The combined
company has been renamed to Spexis AG and is trading on the SIX Swiss Exchange
under the symbol SIX:SPEX. For further information please visit:
www.spexisbio.com (http://www.spexisbio.com/) .

Disclaimer

This press release contains forward-looking statements which are based on
current assumptions and forecasts of Spexis management. Known and unknown
risks, uncertainties, and other factors could lead to material differences
between the forward-looking statements made here and the actual development,
in particular Spexis' results, financial situation, and performance. Readers
are cautioned not to put undue reliance on forward-looking statements, which
speak only of the date of this communication. Spexis disclaims any intention
or obligation to update and revise any forward-looking statements, whether as
a result of new information, future events or otherwise.

Additional features:

File: Spexis to announce FY2021 Financial Results
(https://eqs-cockpit.com/c/fncls.ssp?u=739492cdc357bbb5cd23167f50d838d6)

 

End of ad hoc announcement

 

 Language:     English
 Company:      Spexis AG
               Hegenheimermattweg 125
               4123 Allschwil
               Switzerland
 Phone:        +41 61 567 1600
 Fax:          +41 61 567 1601
 E-mail:       info@spexisbio.com
 Internet:     www.spexisbio.com
 ISIN:         CH0106213793
 Valor:        SPEX
 Listed:       SIX Swiss Exchange
 EQS News ID:  1297747

 

 End of Announcement  EQS News Service

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUKABRUUUORRR